ICRISAT and Eagle Genomics sign Memorandum of Understanding Internationally renowned science-based organisation and pioneering TechBio platform expected to deliver innovative nature-based solutions through exciting public-private relationship Networking microbiome science to tackle the world’s Grand Challenges including effects of climate change Hyderabad, India: A new cooperation framework was signed today between the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) and Eagle Genomics at the International Conference on Innovations to Transform Drylands. …

NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s. NRG Therapeutics is applying breakthrough science in the field of mitochondrial biology to develop first…

In October 2022, the EDPB launched a public consultation on the targeted update of paragraph 73 of the 9/2022 Guidelines on personal data breach notification under the GDPR. Similar to the principles set out in the Working Party 250 Guidelines on personal data breach notification under Regulation 2016/679 (revised in 2018), the EDPB only introduced a major update to data breach notification rules applicable to non-EU companies subject to GDPR. Data breach notification for EU companies For a data breach to be reported by a Controller or Processor established in the EU, the EDPB did not…

Click here to view the February 2023 edition of The Meeting Place

We are launching a new study into Equality, Diversity & Inclusion (ED&I) practices within the UK Life Sciences sector. This important research will help to inform our thinking as we develop and implement an ED&I strategy for the sector that promotes best practices. We want to invite you to take a short survey to help provide an evidence base for the upcoming report. - https://www.surveymonkey.co.uk/r/Z72D2JS The survey closes on 24 February 2023 and takes approximately just 7 minutes to complete. We’ll inform you about the results as soon as they are ready by sending you a copy of…

MAXION THERAPEUTICS Maxion Therapeutics’ $16 million Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases •            Investor syndicate comprised of LifeArc Ventures, Monograph Capital and BGF •            Funding will enable development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform, to overcome challenges with this target class •     …

Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments • Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biology • Reveals future prospects for developing precision medicines to modulate macrophages for the treatment of cancer by targeting tumour associated macrophage (TAMs) in the tumour microenvironment (TME) Edinburgh and Cambridge, UK, 17 February 2023 – The founding scientists behind…

We are delighted to announce that we have entered into a Strategic Partnership for the Development and cGMP Manufacturing Services for Vaccitech’s Adenoviral Vector programme. Pharmaron will become a key part of Vaccitech’s manufacturing network to support novel T cell immunotherapeutics and vaccines from its proprietary ChAdOx1 viral vector platform. The partnership began last year with the technology transfer of a Vaccitech proprietary manufacturing process into Pharmaron’s state-of-the-art Liverpool viral development and GMP manufacturing facilities. This will enable Pharmaron to support…

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT - Eighth new technology partnership with major pharmaceutical and biotech companies since IPO Cambridge, UK, 14 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an additional formulation study agreement with its top five global pharmaceutical partner, building on a collaboration formed in 2022. Under the terms…

Arecor Therapeutics plc (“Arecor” or the “Group”) ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS - Patents further strengthen Group’s extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative Arestat™ technology in development of enhanced formulations of high value biologics Cambridge, UK, 16 February 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce…